Rydapt

Active Ingredient(s): Midostaurin
FDA Approved: * April 28, 2017
Pharm Company: * NOVARTIS PHARMS CORP
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Rydapt Overview

Midostaurin (sold under the name Rydapt) is a multi-targeted protein kinase inhibitor that has been investigated for the treatment of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and advanced systemic mastocytosis. It is a semi-synthetic derivative of staurosporine, an alkaloid from the bacterium Streptomyces' staurosporeus. Contents 1 AML and MDS 2 Systemic mastocytosis 3 Side effects 4 References AML and MDS Midostaurin was found to be active against oncogenic CD...

Read more Rydapt Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Midostaurin

Recent Rydapt Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Midostaurin
  • Capsule: 25mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Rydapt: (1 result)

Sorted by National Drug Code
  • 0078-0698 Rydapt 25 mg Oral Capsule, Liquid Filled by Novartis Pharmaceuticals Corporation

Other drugs which contain Midostaurin or a similar ingredient: (1 result)





Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. Site content is Copyright © 2005-2017 MedsChat.com and is protected under U.S. and International Copyright laws. All Rights Reserved. This page was last updated on 22 July 2017.

We are committed to your privacy.

Copyright © 2005-2017 All Rights Reserved. MedsChat® and The People's Medicine Community® are registered trademarks of Limelight Innovations L.L.C.